Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Filings indexed 1,022 across all filing types
Latest filing 2026-05-06 Interim / Quarterly Rep…
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
10-Q - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
Interim / Quarterly Report
2026-05-06 English
8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
Regulatory Filings
2026-05-06 English
ARS - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
Annual Report
2026-04-28 English
SCHEDULE 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
Major Shareholding Notification
2026-03-27 English
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
Director's Dealing
2026-03-02 English
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
Director's Dealing
2026-02-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.